- Final return
- +27.4%
- vs similar stocks
- +18.3 pp
Dates & source
- Fired
- Apr 2, 2026
- Exit date
- Jul 1, 2026
Buy Approvals Through the Chaos · FDA drug approvals
This looks for drug-company stocks that may rise when they win several FDA approvals (three or more in about six months) during a scary, jumpy market, measured by a high VIX (the market's fear gauge). The idea is that when most drug stocks are being dumped, a fresh approval stands out and gets rewarded more. Heads up: most of this came from one recent, unusually fearful stretch, so it may only work again when the market is similarly stressed.
Newest idea 198 days ago
Updated Oct 17 · 1 feed behind: FDA drug approvals, 1 day · Every feed →
The planned holding period in these tests is 3 months (90 days), from opening to closing an idea.
At the next trading day’s close after the record posts — the first price anyone could have had.
The same hold for every idea — no stop, no target — so nothing flatters the numbers.
At the next available trading close on or after the end of the hold, whatever the price.
Every number on this page uses this sell rule — the other sell rules we tested are under “The full test results and the math” below.
Waiting for source dates
Some inputs have no verified public dates yet, so these are not graded.
Left: did worse · right: did better. Zero matches the comparison. pp = percentage points; the scale adjusts to include the result.
100 tries finished the 3-month test · 0 still open · 201 signals ever
Past results don't predict future ones.
Similar stocks means the index fund for each idea's sector — or the S&P 500 when we can't place its sector. (The S&P 500 for 4 of 100 tries here.)
| How it did against similar stocks | 8.6 percentage points better than similar stocks — over 3 months |
|---|---|
| Range for the average (95%) | +4.3 pp to +13.3 pp vs similar stocks — the range the average probably falls in, not a best-to-worst case |
| Tested on enough tries? | 100 tries on 34 separate days ✓ enough |
| Works in different markets? | 88% from a single year ⚠ one year did most of it |
| Spread across many stocks? | 18% from a single stock ✓ broad |
| Still works without its biggest winner? | +7.3 pp vs similar stocks without BHC ✓ holds up |
The 5 newest of 100 finished ideas: 3 of 5 beat similar stocks — one block each, newest first
did betterdid worseno comparison
LLY · Apr 2, 2026 · Return +27.4% · +18.3 pp vs similar stocks
pp = percentage points above or below the comparable stock return.
This week's list isn't set yet — it's set on the first fresh data of the week of Oct 19.
This rule published no ideas for the week of Oct 12.
Results under the 3-month hold · 0 still open · 100 finished · each idea's sell day is 3 months after it fired · an open idea shows its result so far.
| Stock | Fired | Status | Sell day | Result | vs similar stocks (pp) |
|---|---|---|---|---|---|
| LLY | Apr 2, 2026 | Finished | Jul 1, 2026 | +27.4% | +18.3 pp |
| NVS | Apr 2, 2026 | Finished | Jul 1, 2026 | −0.1% | −9.3 pp |
| PFE | Apr 2, 2026 | Finished | Jul 1, 2026 | −14.5% | −23.6 pp |
| ABBV | Apr 1, 2026 | Finished | Jun 30, 2026 | +17.8% | +10.0 pp |
| TEVA | Mar 31, 2026 | Finished | Jun 29, 2026 | +10.4% | +0.3 pp |
pp = percentage points: the return minus the comparable-stock return. A dash means the comparison is unavailable.
Showing 5 of 100 ideas
pp means percentage points: the difference between two returns. Actual returns are shown in %.
Held a year instead: +40.4% on average (64 tries).
Steadiness (Sharpe ratio) 1.21 — very steady: how even the results were from one try to the next.
Every sell rule we tested, side by side, comes with membership.